Arndt Vogel: NEOPAN Shows PFS Benefit but No OS Gain with FOLFIRINOX in Locally Advanced PDAC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X about a paper by Michel Ducreux et al. published in the Journal of Clinical Oncology:
“PRODIGE 29-UCGI 26 (NEOPAN): Phase III Randomized Trial Comparing FOLFIRINOX or Gemcitabine in Locally Advanced PDAC:
mPFS 9.7 vs 7.7 mo
mOS 15.5 vs 15.5 mo
PFS improved, but more toxicity and no OS benefit. Sufficient data to favour the triplet.”
Title: PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Authors: Michel Ducreux, Romain Desgrippes, Yves Rinaldi, Frédéric Di Fiore, Rosine Guimbaud, Ludovic Evesque, Jean-Baptiste Bachet, Pierre Vanelslander, Thierry Lecomte, Olivier Capitain, Aurélie Parzy, Marion Bolliet, Pierre-Luc Etienne, Julien Forestier, Farid El Hajbi, Anne-Laure Bignon, Valérie Lebrun-Ly, Nicolas De Sousa Carvalho, Matthieu Texier, Olivier Bouche.
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Arndt Vogel.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023